Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June

Core Insights - Valneva SE is actively participating in several investor conferences in June 2024 to discuss its vaccine candidates and commercial business [1][2] Group 1: Vaccine Development - Valneva is developing VLA15, the leading Lyme Disease vaccine candidate, which is currently in Phase 3 development and partnered with Pfizer [2][6] - The company is also advancing VLA1601, a second-generation Zika virus vaccine candidate, which is in Phase 1 clinical development [2][6] Group 2: Commercial Business - Valneva is launching IXCHIQ®, the first and only approved chikungunya vaccine, as part of its growing commercial business [2][6] - The revenues from the commercial business are supporting the advancement of the vaccine pipeline, including the Lyme disease and Zika virus vaccine candidates [6] Group 3: Investor Engagement - Institutional investors can request one-on-one meetings with management at various conferences, including the Jefferies Global Healthcare Conference and Goldman Sachs 45th Annual Global Healthcare Conference [3] - The conferences will feature formats such as fireside chats and investor meetings, providing opportunities for direct engagement with the company's management [3] Group 4: Company Overview - Valneva is a specialty vaccine company focused on developing, manufacturing, and commercializing vaccines for infectious diseases [4] - The company has a strong track record of advancing multiple vaccines from early R&D to approvals and currently markets three proprietary travel vaccines [5]